PGx study results in a 30% reduction in adverse drug reactions

A new study was recently published in the prestigious medical journal, The Lancet, on the clinical utility of Pharmacogenomics (PGx).

The study, known as PREPARE was a trial of almost 7,000 patients seeking care in multiple clinical disciplines. This landmark trial highlights the value of PGx for clinical utility and medication safety.

Using a 12-gene panel, the study demonstrated a 30% decrease in clinically relevant adverse drug reactions, which are the 4th leading cause of death in the United States.